Equibles does not estimate personal net worth.
Get an email with a short summary when Acadia Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get ACAD alertsTom Garner has spoken on 4 earnings calls and 2 other investor events across 1 company, most recently for Acadia Pharmaceuticals Inc on November 4, 2026. Acadia Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acadia Pharmaceuticals Inc includes Catherine Owen Adams (CEO and Board Member), Stephen R. Biggar (Chairman and Board Member), Mark C. Schneyer (CFO) and 7 others.
“I'm pleased to walk you through what was another strong quarter for the commercial business. Starting with debut, Q3 marked yet another record quarter for the brand with $140 million in net sales, representing 39% growth year over year, with almost all of that being driven by volume.”
“What can you say the organization's commercial strengths have been, given that you started off as a relatively small company, and now you have these two products that are analyzing at fairly sizable sales rates. so what's the secret sauce in the commercial side of Acadia so thanks for the question good afternoon…”
“I'm excited to report another strong quarter for debut, which generated $125 million in net sales in the second quarter, representing 30% year-over-year growth, driven almost entirely by volume.”
“So the IP as it stands today is on Trefinitide and Houston Red. So the same IP, the state covers both liquid and stick formulations.”
“Let me dive into the details of our first quarter performance. Starting with debut, I'm pleased to report another excellent quarter with revenue of $101 million, representing 20% year-over-year growth.”
Source not stated
Biotechnology · Healthcare
